Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,831 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Hisamatsu T, et al. Among authors: yokoyama t, yokoyama k. Intest Res. 2018 Jul;16(3):494-498. doi: 10.5217/ir.2018.16.3.494. Epub 2018 Jul 27. Intest Res. 2018. PMID: 30090050 Free PMC article. No abstract available.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.
Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T, Yokoyama T, Okubo T, Hibi T. Suzuki Y, et al. Among authors: yokoyama t. Inflamm Bowel Dis. 2017 May;23(5):822-832. doi: 10.1097/MIB.0000000000001065. Inflamm Bowel Dis. 2017. PMID: 28368909 Free PMC article. Clinical Trial.
Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis.
Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, Nagawa H. Watanabe T, et al. Among authors: yokoyama t. Clin Colorectal Cancer. 2011 Jun;10(2):134-41. doi: 10.1016/j.clcc.2011.03.011. Epub 2011 Apr 22. Clin Colorectal Cancer. 2011. PMID: 21859567
RUNX3 copy number predicts the development of UC-associated colorectal cancer.
Watanabe T, Kobunai T, Ikeuchi H, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, Nagawa H. Watanabe T, et al. Among authors: yokoyama t. Int J Oncol. 2011 Jan;38(1):201-7. Int J Oncol. 2011. PMID: 21109941
3,831 results